Gynae BT 2017

Survival after relapse in PORTEC-1

By site of relapse

By treatment arm

PORTEC Post relapse survival Treatment arm

PORTEC Post relapse survival - no RT arm First failure LRMD

100

100

36 10 10 9 12 9 N F

Vaginal

Pelvic

Meta

Logrank P<.001

75

75

Vaginal

no RT

50

50

25

25

Meta Cumulative percentage

RT 38 34 no RT 58 28 N F

Pelvic

RT

Logrank P<.001

0

0

0

2

4

6

8

years

10

0

2

4

6

8

years

10

At risk:

RT 38

12 32

5

2

1 5

1 1

no RT 58

25

10

r 2004 - 10:13:55

29 Apr 2004 - 10:13:55

➢ Vaginal brachytherapy?

Creutzberg et al, Gynecol Oncol 2003